Evidence map›Paper›PMID 18616639›Full record

ArticleBrain pathology (Zurich, Switzerland)2009

RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs.

Aiala Lorente, Wolf Mueller, Edurne Urdangarín, Paula Lázcoz, Ulrike Lass, Andreas von Deimling, Javier S Castresana

Open access · greenAbstract read
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Ras signaling through RASSF proteins.Seminars in cell & developmental biology · 2016
    Review
  9. Article
  10. Observational
  11. Article
  12. Article
  13. NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Aiala LorenteBrain Tumor Biology Unit, University of Navarra, Irunlarrea 1, Pamplona, Spain.
Wolf Mueller
Edurne Urdangarín
Paula Lázcoz
Ulrike Lass
Andreas von Deimling
Javier S Castresana
Universidad de Navarra · ESHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methylation of CpG islands in gene promoters can lead to gene silencing. Together with deletion or mutation, it may cause a loss of function of tumor suppressor genes. RASSF1A (3p21.3), NORE1A (1q32.1) and BLU (3p21.3) have been shown to be downregulated by methylation in cancer, and PTEN (10q23.3) and MGMT (10q26.1) are located in areas commonly deleted in astrocytomas. MGMT methylation predicts a better response and a longer overall survival in patients with glioblastomas treated with temozolomide. We analyzed 53 astrocytoma samples and 10 high-grade glioma cell lines. Gene expression was assessed by RT-PCR. Bisulfite sequencing, MSP and a melting curve analysis-based real-time PCR were performed to detect promoter methylation. Treatments with 5'-aza-2'-deoxicitidine were applied to restore gene expression in cell lines. Ninety-two percent of tumor samples were methylated for RASSF1A, 30%-57% for BLU and 47% for MGMT, suggesting promoter methylation of these genes to be a common event in glioma tumorigenesis. Only 4% of the tumors revealed a methylated promoter for NORE1A. No association between methylation and loss of expression could be established for PTEN. We identified de novo DNMTs overexpression in a subset of tumors which may explain the methylation phenotype of individual gliomas.

Indexed as

Genes, Tumor SuppressorPromoter Regions, GeneticAdaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsAstrocytomaCell Line, TumorCytoskeletal ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA MethylationDNA Modification MethylasesDNA Repair EnzymesGene ExpressionGliomaHumansMonomeric GTP-Binding ProteinsPTEN PhosphohydrolaseAdaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsCytoskeletal ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA Modification MethylasesDNA Repair EnzymesMGMT protein, humanMonomeric GTP-Binding ProteinsPTEN PhosphohydrolasePTEN protein, humanRASSF1 protein, humanRASSF5 protein, humanTumor Suppressor ProteinsZMYND10 protein, human

Identifiers

PMID18616639
PMCPMC8094756
OpenAlexW1982706153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.